🔗 Share this article

While the United States proceeds with historic changes to its vaccine schedules, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by casting doubt on Covid vaccines throughout the global health crisis and has zeroed in on potential fatalities following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Planned Shifts to Childhood Immunization Schedule

Public health authorities had intended to announce radical revisions to the pediatric immunization program in December, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of alignment with much of the international standard with insufficient data for improved outcomes. This reveal has been delayed until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth individual to lead the division this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has often pushed for ending certain pediatric vaccine recommendations in the US in order to be more like the Danish model, a society with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no apparent experience in drug development, regulation or management, which has been customary for previous heads of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the CDER, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She is not an expert in drug approvals.”

Former heads of the center would “understand legal statutes and the underlying principles of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who ran the center have had.”

CDER has an vast workload at the agency, she pointed out.

“The public just focuses on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars program, OTC medication office and so forth, and all of those need to be supervised,” Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a substantial management element to the job, which manages in excess of 5,000 personnel. “It is a huge management job, if you do it right,” she said.

Response and Controversial Programs

Regarding questions about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among FDA leaders on vaccines, a representative responded that the “inquiries are based on inaccurate presumptions”.

“Her experience is consistent with the duties of her position,” the representative stated, pointing to the time Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a contentious one-day drug-approval program that reportedly concerned her former heads. “By what process are these therapies being picked for this expedited pathway? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards laxer regulations of all drugs, aside from vaccines.”

Documented Track Record on Immunizations

Regarding vaccines, Høeg has a clearer, if problematic, track record, some experts said. She released a research paper using unverified volunteer-provided data to assess the incidence of myocarditis following Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the current administration featured revising guidelines for recently developed shots and halting “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has according to sources proposed preventing young men from obtaining Covid vaccines.

“She is an all-around dogmatist who commences with her preconceived notions and tailors the evidence to fit the science in a highly deceptive, fraudulent way,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg aligned with other skeptics, {like|